Sangamo Therapeutics

Aging Populations And AI Integration Will Expand Gene Therapy Markets

AnalystHighTarget

Not Invested

Community Contributor

Published

10 Aug 25

AnalystHighTarget's Fair Value

US$10.00

93.0% undervalued

10 Sep

US$0.70

-13.6%

3.6%

-13.6%

3.6%

You can edit this narrative until Aug 10 10:23 PM. Then, changes will post as Updates.

Author's Valuation

US$1093.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$10

93.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

35.30%

Biotech revenue growth rate

8.70%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$198.52m

Earnings '28

40.81x

PE Ratio '28

US$8.10b

Market Cap '28

US$8.10b

Market Cap '28

662.86m

No. shares '28

US$12.22

Share Price '28

US$12.22 Share Price '28

Discounted to 2025 @ 6.92% p.a.

US$10.00

Fair Value '25